Understanding how the SARS-CoV-2 glycoprotein and the neurotoxin-like region affects different nAChR subtypes and associated isoforms provides an enriched understanding of COVID-19 pathophysiology and will likely facilitate the development of targeted therapeutics. The gene discussed is CHRNA4; the disease is COVID-19.